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Abstract
It is widely accepted that a deranged immune system plays a key role in the onset and evolution of classic Kaposi
sarcoma (CKS). Nevertheless, the usage of the T-cell receptor (TCR) β-variable (BV) chain repertoire expressed by
peripheral blood lymphocytes in patients with CKS is still unknown. With the aim of providing some further insights
into the complex role of the immune system in CKS pathogenesis, we performed an extensive analysis of the TCR
BV repertoire in both CD4+ and CD8+ T cells in 30 human herpesvirus 8–positive Sardinian patients with CKS and an
equal number of age-matched healthy controls. We used a panel of monoclonal antibodies covering approximately
70% of human BV subfamilies and third complementarity determining region (CDR3) spectratyping. Patients with
CKS showed an increased frequency of BV expansions in both CD4+ and CD8+ lymphocytes, with no prevalent
clones. On spectratyping analysis, most of the 720 BV CDR3 profiles obtained from both CD4+ and CD8+ T cells
in patients with CKS were skewed. In particular, the surprising increase of BV skewing observed in CD4+ lymphocytes
mimics the pattern of progressive TCR BV narrowing described in responses to persistent viral antigen stimula-
tions. Our findings support the hypothesis that CKS evolution is associated with inadequate activation rather than
impairment of the immune system.
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Introduction
Kaposi sarcoma (KS) is an angioproliferative multifocal disease of the
skin occurring in different clinical-epidemiological forms [1], all shar-
ing the same histopathologic features [2] as well as the association
with human herpesvirus 8 (HHV-8) infection [3]. As in other ethnic
groups of Mediterranean descent [4], classic Kaposi sarcoma (CKS) is
very common in the Sardinian population, in which the incidence of
4.06 per 100,000 persons per year among people older than 40 years
represents one of the highest reported worldwide [5]. The onset of
the disease in at-risk individuals is associated with CD8+ T-cell
activation and increased T helper 1–type cytokine production. Such
immunoactivation, mimicking a reactive inflammatory process, induces
the extravasation of lymphomonocytes, spindle cell formation, and
angiogenesis, the histologic hallmarks of KS lesions [6–8]. In this
setting, the latent HHV-8 infection is then reactivated by the same
inflammatory cytokines, which, instead of being effective against the
virus, lead to HHV-8 spreading and progression of the disease [9].
Therefore, the immune response to HHV-8 paradoxically seems to
exacerbate the reactive process, favoring its transition to true sarcoma
lesions. If an acquired specific immunodeficiency occurring in both
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arms of the T-cell immune system modulates non-CKS initiation
and progression [10–12], in the classic variant of KS, a peculiar impair-
ment of the immune system has never been demonstrated. In addition,
several studies focusing on the levels and functions of CD4+ and CD8+
T-lymphocyte subsets have shown conflicting results [13,14].
Because the antigen T-cell responses to infections and tumor anti-
gens, as well as in the context of hypersensitivity and autoimmunity,
are associated with a variety of biased profiles of T-cell receptors (TCRs)
selected from a diverse, naive repertoire [15], we speculated that a
comprehensive analysis of the TCR β-variable (BV) chain repertoire
in isolated CD4+ and CD8+ peripheral blood T lymphocytes could
provide further insights into the immunologic dysregulation charac-
terizing CKS.
The overall expression of the TCR BV repertoire can be screened
by flow cytometry using a panel of monoclonal antibodies directed
against the variable domain of the majority of TCR BV families. Be-
cause robust reference values for the BV repertoire usage in a human
healthy population are available [16], this rapid TCR BV analysis
performed with an appropriate set of monoclonal antibodies is able
to disclose most abnormal T-cell expansions. A further approach to
investigate a possible bias in the TCR BV repertoire is provided by
the so-called spectratyping analysis [17], which determines the profile
of the third complementarity determining region (CDR3) length
distribution in each BV subfamily.
The lack of studies addressing the TCR BV repertoire pattern
in patients with CKS prompted us to investigate peripheral blood
CD4+ and CD8+ subsets by combining flow cytometry and spectra-
typing in a large series of patients with CKS. The presence in Sardinians
of the highest TCR null allele BV20 polymorphism frequency [18],
which could represent a functional bias in an otherwise normally
preserved TCR BV repertoire [19], has been a further stimulus to
investigate the TCR BV repertoire in an ethnically homogenous
CKS group.
Materials and Methods
Patients and Healthy Controls
This study was approved by the local ethic committee. All patients
and healthy controls gave informed consent to their participation to
this study.
All the 30 patients with CKS (22 men and 8 women) were of
Sardinian origin. Table 1 depicts the main clinical features of patients
with CKS. Their median age was 70 years (range, 49-85 years). In
each case, the diagnosis of CKS was confirmed by histologic examina-
tion. All patients were negative for HIV and none of them presented
concomitant malignancies. Possible iatrogenic causes of KS were ex-
cluded. Because a universally accepted CKS staging system is still
lacking, we classified our CKS series using the modified version [20]
of the Mitsuyasu-Groopman classification [21]. Accordingly, 23 pa-
tients (77%) showing only cutaneous involvement were classified as
having stage I to II disease, whereas the remaining 7 (23%) with sys-
temic involvement were considered to have stage III to IV disease.
The timing of the analysis from diagnosis varied from 1 to 240 months
(mean, 59 months). Fifteen patients (50%) had no previous therapy,
eight (27%) had undergone surgical excision or cryotherapy for their
lesions, whereas seven (23%) had been treated with an anthracycline-
based regimen. At the time of evaluation, almost all the patients had
a stable disease and only one was in progression.
Thirty age-matched healthy Sardinian people (15men and 15women)
were included in the study as normal controls. Their main characteristics
are summarized in Table 1.
All patients and controls were tested for HHV-8 serostatus by
using indirect immunofluorescence for the detection of antibodies
to viral lytic antigens combined with enzyme-linked immunosorbent
assay for the detection of specific antibodies to the K8.1 HHV-8 pro-
tein, as reported elsewhere [22]. Positivity was attributed to any
sample that had positive results on both tests.
CD4+ and CD8+ T-cell Separation
Peripheral blood mononuclear cells were prepared by Ficoll-Hypaque
(Sigma Diagnostic, St. Louis, MO) gradient centrifugation. Cells were
separated into CD4+ and CD8+ subsets by positive selection using
antibody-coated immunomagnetic beads (Dynabeads; Dynal, Oslo,
Norway) for 30 minutes at 4°C on a rotating shaker followed by
magnetic isolation. Guanidinium thiocyanate–phenol–chloroform
(Invitrogen, Paisley, United Kingdom) was added to both cell fraction
pellets, and they were stored at −80°C until RNA extraction.
Flow-Cytometry
We first determined the frequency of CD4+, CD8+ and natural
killer T lymphocytes by using anti-CD3, CD4, CD8, and CD16/
56 antibodies.
Flow cytometric analysis of the TCR BV repertoire was performed
with the IOTest Beta Mark Kit (Beckman Coulter, San Diego, CA),
according to the manufacturer’s instructions. Briefly, 1 × 106 cells/
sample were stained with a panel of 24 BV family-specific antibodies,
combined in groups of three in eight tubes, one antibody being
conjugated to fluorescein isothiocyanate, another to phycoerythrin,
and the third to both fluorescein isothiocyanate and phycoerythrin.
Costaining was performed with anti-CD4+ or anti-CD8+ peridinin
chlorophyll protein complex (PerCp) (all antibodies from Becton
Dickinson, San Jose, CA). Samples were acquired by a FACSort flow
cytometer using CELLQuest software. A lymphocyte gate was estab-
lished based on forward and side scatter characteristics. The relative
Table 1. Summary of Patients and Healthy Controls’ Characteristics.
Characteristics
Patients
n 30
Age, median (range), y 70 (49-85)
Sex, n (%)
Male 22 (73)
Female 8 (27)
Disease stage, n (%)
I/II 23 (77)
III/IV 7 (23)
Previous therapy, n (%)
No therapy 15 (50)
Surgery/cryotherapy 8 (27)
Anthracycline-based regimen 7 (23)
State of disease, n (%)
Stable 29 (97)
In progression 1 (3)
Healthy controls
n 30
Age, median (range), y 72 (52-88)
Sex, n (%)
Male 15 (50)
Female 15 (50)
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representation of a given BV subfamily was expressed as the percentage
of cells stained with the family-specific antibody among CD4+ or
CD8+ T cells. A BV expansion was defined as any value of BV family
expression higher than the mean plus 3 SD calculated in normal con-
trols. Of note, the mean expression values of each BV subfamily in
our healthy controls were very similar to the reported reference BV
values [16]. Likely because of their older age, our controls showed a
higher frequency of expanded BV subfamilies.
CDR3 Spectratyping
The RNAwas isolated from each subset of cells as described elsewhere
[23]. Complementary DNA was synthesized by using SuperScript III
reverse transcriptase and random hexamer primers (Invitrogen, Paisley,
United Kingdom) according to the manufacturer’s instructions. Poly-
merase chain reaction (PCR) was performed in a volume of 25 μl
comprising 1× PCR buffer, 2.5 mM magnesium chloride, 1 U of
AmpliTaqGold (Applied Biosystems, Foster City, CA), 200 μMdeoxy-
ribonucleoside triphosphate (dNTPs), and 500 nM of 1 of 24 TCR BV
primers combined with 1 β-constant primer conjugated to the fluores-
cent dye 6-carboxyfluorescein amino hexy [24]. The sequences of the
TCR BV and β-constant primers were described previously [17]. The
PCR conditions were 95°C for 10 minutes followed by 36 cycles of
94°C for 20 seconds, 55°C for 40 seconds, 72°C for 40 seconds, and
a final extension at 72°C for 5 minutes. The PCR fragments were then
run on an ABI Prism 310 Genetic Analyzer (Applied Biosystems), and
data were collected and analyzed by the ABI Prism GeneScan Analysis
software version 3.7 (Applied Biosystems).
Spectratyping Analysis
Analysis of spectratyping data was performed by analyzing profiles
by peak area and shape to establish the degree of skewing and oligo-
clonality. In particular, each spectratyping profile was assessed follow-
ing previously described criteria [25]. A profile was defined as normal
if showing a Gaussian, bell-shaped distribution, with discrete peaks
spaced by three nucleotides. Evidence of oligoclonal expansion or
skewing within each BV was assessed by calculating the relative fluo-
rescence intensity (RI) of each peak (RI = peak area / total BV peak
area). A profile was defined as skewed if: 1) a dominant peak with a
RI greater than 50% of the total peak area was observed, 2) two domi-
nant peaks were present and RI of each peak was greater than 25%
of the total peak area, or 3) there were multiple peaks differing from
a Gaussian pattern and the RI of dominant peaks was greater than
25% of the total peak area. The first of these three criteria (the presence
of a dominant peak with an RI >50% of the total peak area) was used
to specifically identify oligoclonal BVs. The percentages of skewed and
oligoclonal BV subfamilies were calculated among the total number of
BVs analyzed in each patient.
DNA Amplification
DNA was isolated from the peripheral blood mononuclear cells of
25 patients with CKS.
DNA samples were amplified by PCR using a DNA thermal cycler
(Applied Biosystems). The PCR mix contained 2.5 μl of 10× PCR
buffer (containing 25 mM magnesium chloride), 1 μl of deossi-
nucleotide-triphosphates (final concentration, 10 mM each), 0.5 μl
of Taq polymerase (10 U/μl), 50 pmol of each primer, and 500 ng
of genomic DNA. The amplification profile was 40 cycles of 1 minute
at 94°C, 1 minute at 60°C, and 2 minutes at 72°C, preceded by 1 min-
ute at 94°C, and followed by 5 minutes at 72°C. The specific primers
5-ATTCATCAATGGCCAGCGAC-3 and 5-GGAGCTTCTTAG-
AACTCAG-3 were used as described elsewhere [26].
Restriction Enzyme Digestion Analysis
A 10-μl quantity of the amplified DNA was digested with 10 U of
KpnI (Invitrogen, Carlsbad, CA) with the addition of the manu-
facturer’s 10× digestion buffer. Restriction enzyme–digested PCR prod-
ucts were subjected to electrophoresis in a nondenaturant 3% agarose
gel. The gel was stained with ethidium bromide and visualized by
ultraviolet illumination. The analyzed single nucleotide polymorphism
involves a C-to-T base transition at position 524 in the TCR BV20
gene segment. Hence, the resulting null allele (allele 2) carries in the
BV20 gene segment the stop codon CGA>TGA responsible for the
deletion of the restriction site for the KpnI enzyme. A single electro-
phoresis band at 235 bp corresponds to the homozygosity for allele 2.
DNA from homozygotes for allele 1, that is, the BV20 gene segment
nonmutated at position 524, is identified by the presence of two
bands at 100 and 135 bp, whereas heterozygous subjects show three
bands at 235, 135, and 100 bp. To exclude misinterpretation be-
cause of partial digestions, PCR products from subjects known to
be homozygous for allele 1 and allele 2 were included in each set of
digestions. Gene and genotype frequencies of TCR BV20 alleles were
determined by counting.
Statistical Analysis
The comparison between the mean expression of each BV subfamily
in patients and controls was performed using the nonparametric Mann-
Whitney test. The Student’s t test was used to assess the differences in
the percentage of BV expansions determined by flow cytometry be-
tween patients and controls as well as in the percentage of skewed or
oligoclonal BV subfamilies determined by spectratyping. All quoted
P values are two-sided with P < .05 considered statistically significant.
Results
HHV-8 Serostatus of Patients with CKS and Healthy Controls
All the patients with CKS had antibodies against HHV-8, whereas
among the 30 healthy controls, 13 (43%) were positive for HHV-8.
Patients with CKS Show an Increased Frequency of
Lymphocyte Expansions in Both CD4+ and CD8+ T cells
The mean frequencies of CD3+, CD4+, CD8+, and CD16/CD56+
T cells were superimposable in patients and controls (65% vs 68%,
40% vs 41%, 22% vs 23%, and 20% vs 21%, respectively). On the
whole, the mean expression levels of almost all the BV subfamilies
did not show a significant difference among patients and controls
in both CD4+ and CD8+ T cells. Only the BV17 subfamily in the
CD4+ fraction and BV4 and BV7-1 in CD8+ T cells in patients with
CKS showed significantly increased expression levels in comparison
with healthy controls, whereas a decreased expression of BV9 in
CD8+ T cells of patients with CKS was also demonstrated (Figure 1).
This variability could just reflect the expansions of several BV sub-
families described below.
Because there were no significant differences in the mean frequencies
of the expanded BV subfamilies between HHV-8+ and HHV-8−
healthy controls (data not shown), we could assume that, in such a
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cohort, the expression of the T-cell repertoire is rather homogenous. In
comparison with controls, patients with CKS were characterized by a
significantly higher frequency of expanded BV subfamilies in both the
CD4+ subset (3.6% vs 1.5%, P < .01) and the CD8+ one (7.3% vs
3.0%, P < .005; Figure 2). The relative size of the whole 79 T-cell
expansions detected in patients with CKS ranged from 1.1% (involving
BV11) to 25.7% (BV21.3) in the CD4+ subset and from 1.1% (BV4)
to 36.6% (BV17) in the CD8+ one. As already reported [16], the
Figure 2.Mean frequency of the expanded BV subfamilies detected by flow cytometry in CD4+ and CD8+ T cells in patients and controls.
Patients were characterized by a higher frequency of expanded BV subfamilies than normal controls, both in the CD4+ subset (3.6% vs
1.5%, P < .01) and in the CD8+ one (7.3% vs 3.0%, P < .005). In both controls and patients, the frequency of expanded BV subfamilies
was significantly higher in CD8+ than in CD4+ cells. A BV expansion was defined as any value of BV family expression higher than the
mean +3 SD calculated in normal controls.
Figure 1.Mean BV subfamily percentage expression on flow cytometry in CD4+ and CD8+ T cells in patients and controls. Patients and
controls showed similar expression in most BVs. Nonetheless, in patients, we found a significantly increased expression (BV marked
with an asterisk [*]) only in the BV17 (mean 5.1% vs 4.1%, P < .05) of the CD4+ T cells and in the BV4 (mean 1.0% vs 0.5%, P < .001)
and the BV7.1 (mean 4.3% vs 3.3%, P < .05) of the CD8+ subset. Conversely, we found a decreased expression (BV marked with a
pound sign [#]) only in the BV9 (mean 1.4% vs 1.6%, P < .05) of CD8+ T cells.
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frequency of expanded BV subfamilies in controls was significantly
higher in CD8+ than in the CD4+ T cells (P < .05), and this was also
observed in patients with CKS (P < .01; Figure 2). No relationship was
found between the frequency of BV expansions and staging or previous
treatment of patients with CKS. Finally, no preferential BV subfamily
expansions were found among patients.
Patients with CKS Show a Contracted TCR Repertoire on
CDR3 Spectratyping Analysis
Of note, the spectratyping method we used could detect a mean
of 22 (range, 15-24) and 23 (range 16-24) specific CDR3 BV profiles
per sample in CD4+ and CD8+ T cells, respectively. A representa-
tive CDR3 TCR BV spectratyping profile obtained in the CD4+ and
CD8+ T cells isolated from the peripheral blood of one of the patients
is shown in Figure 3. On the whole, 632 and 595 BVs were available
for statistical comparison in CD4+ T cells and 633 and 585 BVs in
CD8+ T cells in controls and patients with CKS, respectively.
Taking into account that HHV-8+ and HHV-8− healthy controls
did not show significant differences in the mean incidence of BVs
showing a skewed or oligoclonal profile in both CD4+ and CD8+
T cells (data not shown), we compared the degree of BV skewing
between patients with CKS and the whole group of controls. A signifi-
cantly higher frequency of skewness in both the CD4+ subset (43%
vs 25%, P < .0005) and CD8+ T cells (86% vs 75%, P < .005) was
found in patients with CKS (Figure 4A). As expected, the occurrence
of skewed BV subfamilies was significantly more frequent in CD8+
than in CD4+ T cells (P < .0001) in both groups (Figure 4A).
Nevertheless, the incidence of BVs with a clear oligoclonal profile
was similar between patients and controls (2.0% vs 1.8% in CD4+
T cells and 10.4% vs 11.3% in CD8+ T cells, respectively; Figure 4B).
Once again, in both patients and controls, the mean frequency of
oligoclonal BVs was significantly higher in the CD8+ than in the
CD4+ subset (P < .0001; Figure 4B).
We then compared the findings obtained by spectratyping and
flow cytometry in patients to dissect if expanded lymphocyte sub-
populations were characterized by either a polyclonal or an oligo-
clonal pattern. According to the criteria we used to define T-cell
expansions on flow cytometry and the degree of BV CDR3 profile
skewness on spectratyping analysis, we found that, of the 27 ex-
panded BVs in CD4+ T cells, 61% of them showed a skewed
CDR3 profile, 8% were oligoclonal, and 31% were Gaussian. In
CD8+ T cells, of the 52 expanded BVs, 66%, 23%, and 11% showed
a skewed, oligoclonal, and Gaussian CDR3 profiles, respectively (data
not shown).
Finally, the frequency of skewed and oligoclonal BVs did not
correlate with the stage of the disease or with previous treatments
(data not shown). Moreover, when we investigated the prevalence
of skewing or oligoclonal patterns involving specific BV subfamilies
in patients with CKS, we could not detect any prevalent usage of the
TCR repertoire.
Genotypic Analysis in Patients with CKS Showed a Frequency
of Homozygotes for the BV20S1 Null Allele Similar to
That Reported in the Whole Sardinian Population
After DNA amplification and KpnI enzyme digestion, 4 (17%) of
the 24 patients with CKS analyzed resulted homozygous for the so-
called null allele (allele 2) and 12 of them (50%) were heterozygous.
These incidences correspond to those previously reported in the whole
Sardinian population [18].
Discussion
CKS is a reactive inflammatory-angiogenic process of the skin of poly-
clonal origin which can progress into a true sarcoma involving visceral
organs in rare cases. The HHV-8 persistent infection characterizes the
course of this rare disease, but it is well recognized that an altered
Figure 3. Representative spectratyping profiles of the CDR3 in CD4+ and CD8+ T cells of one of the patients. According to the criteria
described in Materials and Methods, BVs 8, 10, 13, 15, 16, 19, 20, 21, and 23 were skewed; BVs 1 and 14 were oligoclonal; whereas the
remaining BVs were Gaussian in CD4+ T cells. In CD8+ T cells, BVs 1, 3, 14, 15, 19, and 22 were oligoclonal, whereas all the other BVs
were skewed with the exception of BV24, which was Gaussian.
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cellular immune response also plays an important role in its patho-
genesis and evolution [2,10,11,27]. Because the TCR BV repertoire
generated within an immune response can undergo some well-defined
alterations, such as restrictions and immunodominant expansions, we
performed an extensive TCR repertoire analysis on CD4+ and CD8+
circulating cells of patients with CKS by combining flow cytometry
and CDR3 spectratyping. We found that, in patients with CKS,
peripheral blood lymphocytes are characterized by an increased fre-
quency of expanded subpopulations occurring in both the CD4+ and
the CD8+ T-cell subsets. Moreover, we could not find any preferential
usage of specific BV subfamilies. These findings recall the lack of TCR
immunodominance and the weak immunogenicity of HHV-8–specific
epitopes emerging from preliminary in vitro and ex vivo studies on
CD8+ T-cell responses against these epitopes [27–30]. Whether these
lymphocyte expansions are triggered in the course of CKS by aber-
rantly expressed oncogenes and fusion genes in neoplastic cells or by
HHV-8—alone or in association with other infectious agents—is yet
to be solved.
Because the specificity of T lymphocytes is a function of the CDR3
BV structure, the characterization of CDR3 sequence variations should
be considered a measure of T-cell diversity in an antigen driven T-cell
repertoire. Being aware of the limits of the spectratyping, which is able
to merely mirror the range of CDR3 length variations [31], we tried
to further dissect the TCR BV repertoire pattern by comparing the
CDR3 BV profiles obtained in each patient by flow cytometry and
spectratyping. In comparison with the healthy population, patients
with CKS show an increased degree of skewing within the TCR BV
repertoire not only in CD8+ lymphocytes but also in CD4+ T cells,
suggesting that this constrained TCR BV repertoire is either improperly
or heterogeneously stimulated in the various phases of CKS. This
hypothesis is supported by the observation that CD8+ T cells infil-
trating the CKS cutaneous lesions are polyclonal [32] and mostly not
epitope specific [27]. Noteworthy, a nonspecific activation of the T-cell
immune system occurs in diseases, which, although quite different from
CKS, are characterized by an evident immune dysregulation [33–35].
Although all these cases are dominated by an evident restriction of
the TCR BV repertoire confined to the CD8+ T-cell compartment,
our CDR3 spectratyping data show that the TCR BV repertoire is
largely restricted also in circulating blood CD4+ lymphocytes. To note,
the increased CD4+ TCR BV repertoire skewness occurs in both the
Figure 4. Representation of the mean frequency of CDR3 spectratyping profiles in the BV subfamilies observed in patients with CKS and
controls. (A) Patients were characterized by a significantly higher frequency of BV subfamilies showing a skewed profile in both CD4+
T cells (43% vs 25%, P< .0005) and in the CD8+ subset (86% vs 75%, P< .005). As expected, the occurrence of skewed BV subfamilies
was significantly more frequent in CD8+ than in CD4+ cells in both controls and patients (P < .0001). (B) We found a similar incidence
of BVs with an oligoclonal CDR3 spectratyping profile between patients and controls in both T-cell subpopulations (2.0% vs 1.8% in
CD4+ T cells and 10.4% vs 11.3% in CD8+ ones). Once again, the frequency of oligoclonal BV subfamilies was significantly higher in
CD8+ than in CD4+ cells in both controls and patients (P < .0001). NS indicates not significant.
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expanded and the nonexpanded BV subfamilies, suggesting that the
entire TCR repertoire is somehow limited in diversity in CKS. More-
over, it has been experimentally shown that the development of TCR
diversity during thymic selection can be limited to only a few possible
gene rearrangements [36]. These findings obtained from CD4+ lym-
phocyte analysis seem to mimic the pattern of progressive TCR BV
narrowing described in response to persistent viral antigens [37,38].
In conclusion, our CDR3 spectratyping data, providing some
further clues on the complex role of the immune system in CKS
pathogenesis, could support the hypothesis that an inadequate activa-
tion rather than an overall impairment of the immune system could
characterize the evolution of CKS.
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